ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION RECIPIENT

Clinical trials for ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION RECIPIENT explained in plain language.

Never miss a new study

Get alerted when new ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION RECIPIENT trials appear

Sign up with your email to follow new studies for ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION RECIPIENT, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 3 Not yet recruiting 1 Completed 1

New drug combo tested to fight Leukemia's return after transplant

Disease control Completed

This early-stage study tested two immunotherapy drugs, nivolumab and ipilimumab, in patients with high-risk or returning acute myeloid leukemia or myelodysplastic syndrome who had already received a donor stem cell transplant. The main goals were to find safe doses and check for …

Matched conditions: ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION RECIPIENT

Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control

Last updated Mar 25, 2026 14:07 UTC

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION RECIPIENT

Get alerted when new ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION RECIPIENT trials appear

New drug combo tested to fight Leukemia's return after transplant